Table 1.

Clinical Outcomes from CART FDA Approval Trials.

CART Trial	CART Therapy	Phase	Indication	Minimum # of Prior Therapies	ORR (CR/PR)
JULIET	Tisagenlecleucel	Phase II	R/R DLBCL post or ineligible for ASCT	2	52% (40%/12%)
ELIANA*	Tisagenlecleucel	Phase II	R/R B-ALL (<25 yo)	1	81%* (-/-)
ZUMA-1	Axi-cel	Phase II	R/R DLBCL, PMBL, or TFL	2	82% (54%/28%)
Transcend NHL 001	Liso-cel	Phase I	R/R DLBCL, FL, PMBL	2	73% (53%/20%)
ZUMA-2	KTE-X19	Phase II	R/R MCL	3	85% (59%/26%)
KarMMA	Ide-Cel	Phase II	R/R Multiple Myeloma	3	73% (33%/40%)

ORR (objective response rate), CR (complete response rate), PR (partial response rate), R/R (relapsed/refractory), ASCT (autologous stem cell transplant), PMBL (Primary Mediastinal B cell lymphoma), FL (Follicular Lymphoma), TFL (transformed Follicular Lymphoma), MCL (Mantle Cell Lymphoma).

Currently approved CART therapies by trial name, indication, and clinical response rates.

*Prior therapy could include autologous stem cell transplant, ORR, Overall remission rate.